Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6959MR)

This product GTTS-WQ6959MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ6959MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2463MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 181
GTTS-WQ1730MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ADC-1013
GTTS-WQ15486MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ3173MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AR-101
GTTS-WQ14297MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG-7221
GTTS-WQ3813MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ14795MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-70
GTTS-WQ1876MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGEN1884
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW